

Financial Statements of

**THE LEUKEMIA & LYMPHOMA
SOCIETY OF CANADA/
SOCIÉTÉ DE LEUCÉMIE &
LYMPHOME DU CANADA**

And Independent Auditor's Report thereon

Year ended June 30, 2025

**KPMG LLP**

Vaughan Metropolitan Centre
100 New Park Place, Suite 1400
Vaughan, ON L4K 0J3
Canada
Telephone 905 265 5900
Fax 905 265 6390

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of
The Leukemia & Lymphoma Society of Canada/
Société de Leucémie & Lymphome du Canada

Opinion

We have audited the financial statements of The Leukemia & Lymphoma Society of Canada/Société de Leucémie & Lymphome du Canada (the Entity), which comprise:

- the statement of financial position as at June 30, 2025
- the statement of revenue and expenses for the year then ended
- the statement of changes in fund balances for the year then ended
- the statement of cash flows for the year then ended
- and notes to the financial statements, including a summary of significant accounting policies

(Hereinafter referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Entity as at June 30, 2025, and its results of operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the **"Auditor's Responsibilities for the Audit of the Financial Statements"** section of our auditor's report.

We are independent of the Entity in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Entity's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Entity's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.

The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.



Page 3

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

A handwritten signature in black ink that reads 'KPMG LLP'. The signature is written in a cursive, stylized font. A horizontal line is drawn underneath the signature, starting from the left and extending to the right, ending under the 'P'.

Chartered Professional Accountants, Licensed Public Accountants

Vaughan, Canada

October 29, 2025

THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA/ SOCIÉTÉ DE LEUCÉMIE & LYMPHOME DU CANADA

Statement of Financial Position

June 30, 2025, with comparative information for 2024

	2025	2024
Assets		
Current assets:		
Cash and cash equivalents (note 2(a))	\$ 2,970,057	\$ 3,624,050
Sundry receivables	381,061	924,293
Prepaid expenses	580,952	325,077
	3,932,070	4,873,420
Investments (note 2(b))	8,879,679	7,878,636
Capital and intangible assets (note 3)	705,180	563,029
	\$ 13,516,929	\$ 13,315,085

Liabilities and Fund Balances

Current liabilities:		
Accounts payable and accrued liabilities (note 4)	\$ 993,547	\$ 668,455
Grants and fellowships payable	—	421,743
Deferred revenue (note 5)	688,607	686,063
	1,682,154	1,776,261
Fund balances:		
Operating fund:		
Invested in capital and intangible assets	705,180	563,029
Unrestricted fund	2,334,346	2,199,676
	3,039,526	2,762,705
Externally restricted fund (note 6)	2,330,545	2,149,324
Internally restricted fund (note 7)	6,000,000	6,000,000
Endowment fund (note 8)	464,704	626,795
	11,834,775	11,538,824
Commitments (note 10)		
Guarantees (note 13)		
	\$ 13,516,929	\$ 13,315,085

See accompanying notes to financial statements.

On behalf of the Board:

_____ Director

_____ Director

THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA/ SOCIÉTÉ DE LEUCÉMIE & LYMPHOME DU CANADA

Statement of Revenue and Expenses

Year ended June 30, 2025, with comparative information for 2024

	2025		2024	
	Operating fund	Externally restricted fund	Total	Total
Revenue:				
Contributions	\$ 12,945,270	\$ 521,335	\$ 13,466,605	\$ 13,405,555
Less direct event fundraising expenses (note 11)	927,730	—	927,730	994,449
	12,017,540	521,335	12,538,875	12,411,106
Bequests	2,332,091	—	2,332,091	894,865
Investment and other income (note 9)	838,157	325,898	1,164,055	1,270,567
	15,187,788	847,233	16,035,021	14,576,538
Expenses (note 12):				
Program services:				
Research	—	3,552,726	3,552,726	3,203,555
Public education	2,756,915	—	2,756,915	2,497,463
Patient support	2,470,154	445,949	2,916,103	2,848,213
	5,227,069	3,998,675	9,225,744	8,549,231
Support services:				
General fundraising (note 11)	3,542,408	—	3,542,408	3,438,974
Management and general (note 9)	2,970,918	—	2,970,918	3,149,078
	6,513,326	—	6,513,326	6,588,052
	11,740,395	3,998,675	15,739,070	15,137,283
Excess (deficiency) of revenue over expenses	\$ 3,447,393	\$ (3,151,442)	\$ 295,951	\$ (560,745)

See accompanying notes to financial statements.

THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA/ SOCIÉTÉ DE LEUCÉMIE & LYMPHOME DU CANADA

Statement of Changes in Fund Balances

Year ended June 30, 2025, with comparative information for 2024

						2025	2024
	Operating fund						
	Invested in capital and intangible assets	Unrestricted fund	Externally restricted fund (note 6)	Internally restricted fund (note 7)	Endowment fund (note 8)	Total	Total
Fund balances, beginning of year	\$ 563,029	\$ 2,199,676	\$ 2,149,324	\$ 6,000,000	\$ 626,795	\$ 11,538,824	\$ 12,099,569
Excess (deficiency) of revenue over expenses	(50,786)	3,498,179	(3,151,442)	—	—	295,951	(560,745)
Interfund transfers - externally restricted	—	(3,170,572)	3,412,391	—	(241,819)	—	—
Interfund transfers - endowment investment income	—	—	(79,728)	—	79,728	—	—
Investment in capital and intangible assets	192,937	(192,937)	—	—	—	—	—
Fund balances, end of year	\$ 705,180	\$ 2,334,346	\$ 2,330,545	\$ 6,000,000	\$ 464,704	\$ 11,834,775	\$ 11,538,824

See accompanying notes to financial statements.

THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA/ SOCIÉTÉ DE LEUCÉMIE & LYMPHOME DU CANADA

Statement of Cash Flows

Year ended June 30, 2025, with comparative information for 2024

	2025	2024
Cash provided by (used in):		
Operating activities:		
Excess (deficiency) of revenue over expenses	\$ 295,951	\$ (560,745)
Items not involving cash:		
Amortization	50,786	116,747
Change in unrealized gain on investments	(688,552)	(178,966)
Change in non-cash operating working capital:		
Sundry receivables	543,232	(638,805)
Prepaid expenses	(255,875)	353,680
Accounts payable and accrued liabilities	325,092	139,052
Grants and fellowships payable	(421,743)	(2,217,277)
Deferred revenue	2,544	206,983
	(148,565)	(2,779,331)
Investing activities:		
Purchases of investments	(312,491)	(748,833)
Additions to capital and intangible assets	(192,937)	(176,519)
	(505,428)	(925,352)
Decrease in cash and cash equivalents	(653,993)	(3,704,683)
Cash and cash equivalents, beginning of year	3,624,050	7,328,733
Cash and cash equivalents, end of year	\$ 2,970,057	\$ 3,624,050

See accompanying notes to financial statements.

THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA/ SOCIÉTÉ DE LEUCÉMIE & LYMPHOME DU CANADA

Notes to Financial Statements

Year ended June 30, 2025

The Leukemia & Lymphoma Society of Canada/Société de Leucémie & Lymphome du Canada (the "Organization") is a volunteer-driven organization with a mission to establish, promote and support medical and scientific research towards cures and/or treatment of blood-related cancers; educate the general public and the medical and scientific community about developments in the prevention, diagnosis and treatment of blood-related cancers; and support community service programs and access to such programs for patients suffering from blood-related cancers, including leukemia, lymphoma, Hodgkin's disease and myeloma.

The Organization was previously incorporated without share capital under the Canada Corporations Act and on October 27, 2014, the Organization was continued under the Canada Not-for-profit Corporations Act. The Organization is registered as a charitable organization under the Income Tax Act (Canada) and is, therefore, not subject to income taxes if certain disbursement requirements are met.

1. Significant accounting policies:

These financial statements have been prepared by management in accordance with Canadian accounting standards for not-for-profit organizations in Part III of the Chartered Professional Accountants of Canada Handbook.

(a) Fund accounting:

The Organization follows the restricted fund method of accounting for contributions.

The Operating fund accounts for the Organization's program delivery and administrative activities.

The Externally restricted fund reports only restricted resources that are to be used for special purposes. The purposes are determined by the restrictions imposed by the contributors.

The Endowment fund reports resources contributed for endowment purposes. Investment income earned on resources of the Endowment fund is reported in the Restricted or Operating fund depending on the nature of any restrictions imposed by contributors of funds for endowment.

THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA/ SOCIÉTÉ DE LEUCÉMIE & LYMPHOME DU CANADA

Notes to Financial Statements (continued)

Year ended June 30, 2025

1. Significant accounting policies (continued):

(b) Revenue recognition:

Unrestricted contributions are recorded as revenue of the Operating fund when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured. Contributions received from fundraising events that have not been completed are deferred until completion of the event. Other restricted contributions are deferred until such time as they are spent in accordance with the donor's restrictions, which may include general operations of future periods.

Restricted contributions for research are recognized as revenue of the Restricted fund.

Externally restricted endowment contributions are recognized as revenue of the Endowment fund.

Bequests are recorded as revenue when received or receivable if the underlying wills have been declared valid by the probate court and no other conditions are required to be met.

Restricted and unrestricted investment income is recognized as revenue when earned. Investment income, which is recorded on the accrual basis, includes income from pooled funds, interest, net unrealized gain/loss on investments, and net realized gain/loss on sale of investments.

(c) Cash and cash equivalents:

Cash and cash equivalents include cash on account and cashable guaranteed investment certificates.

(d) Financial instruments:

Financial instruments are recorded at fair value on initial recognition. Equity instruments that are quoted in an active market are subsequently measured at fair value. All other financial instruments are subsequently recorded at cost or amortized cost, unless management has elected to carry the instruments at fair value. The Organization has elected to carry all financial investments at fair value.

THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA/ SOCIÉTÉ DE LEUCÉMIE & LYMPHOME DU CANADA

Notes to Financial Statements (continued)

Year ended June 30, 2025

1. Significant accounting policies (continued):

Transaction costs incurred on the acquisition of financial instruments measured subsequently at fair value are expensed as incurred.

Financial assets are assessed for impairment on an annual basis at the end of the fiscal year if there are indicators of impairment. If there is an indicator of impairment, the Organization determines if there is a significant adverse change in the expected amount or timing of future cash flows from the financial asset. If there is a significant adverse change in the expected cash flows, the carrying value of the financial asset is reduced to the highest of the present value of the expected cash flows, the amount that could be realized from selling the financial asset or the amount the Organization expects to realize by exercising its right to any collateral. If events and circumstances reverse in a future period, an impairment loss will be reversed to the extent of the improvement, not exceeding the initial impairment charge.

(e) Capital and intangible assets:

Purchased capital and intangible assets are recorded at cost. Repairs and maintenance costs are charged to expense. Betterments which extend the estimated life of an asset are capitalized. When conditions indicate that the assets no longer contribute to the Organization's ability to provide goods or services, or that the value of future economic benefits or service potential associated with the long-lived assets are less than their net carrying amounts, long-lived assets, including capital assets and intangible assets, are written down to fair value or replacement cost to reflect partial impairments.

Capital and intangible assets are amortized over their estimated useful lives on a straight-line basis at the following rates:

Office furniture and equipment	2 - 10 years
Website	3 years
Intangible asset - software	2 years

THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA/ SOCIÉTÉ DE LEUCÉMIE & LYMPHOME DU CANADA

Notes to Financial Statements (continued)

Year ended June 30, 2025

1. Significant accounting policies (continued):

(f) Gifts-in-kind:

The value of donated materials and services contributed to the Organization are not recognized in the financial statements because of the difficulty in determining their fair value.

Included in contributions on the statement of revenue and expenses is \$206,650 (2024 - \$82,731) in donated shares.

(g) Cloud computing arrangements:

On July 1, 2024, the Organization adopted AcG-20, Customer's accounting for cloud computing arrangements ("AcG-20"). In accordance with AcG-20, the Organization has elected to apply the simplification approach in accounting for its expenditures in a cloud computing arrangement. Advance lumpsum payment for the use of software is recognized as a prepaid expense.

Included in allocated expenses are \$339,600 (2024 - \$315,740) software subscription fees to support project management, HR management, procurement management, and to facilitate donation processing.

(h) Research grants:

Research grants are approved by the Board of Directors ("Board") and are recognized as expense when the conditions set out in the funding agreement is met. The budgets for multi-year grants, which are generally two to three years in length, are approved on an annual basis, and may be terminated at the discretion of the Board. Estimated future research grants is disclosed in the notes to the financial statements (note 10(b)). Grant refunds and cancellations are recognized in the year the recipient and the Organization mutually terminate the contract, and the amount is estimable.

THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA/ SOCIÉTÉ DE LEUCÉMIE & LYMPHOME DU CANADA

Notes to Financial Statements (continued)

Year ended June 30, 2025

1. Significant accounting policies (continued):

(i) Allocation of expenses:

The Organization classifies expenses on the statement of revenue and expenses by function. Certain officers and employees perform a combination of program and support service functions; as a result, salaries are allocated based on functional activity. Other costs, including printing, postage and professional fees, have been allocated on an appropriate basis between the program and support services benefited.

(j) Use of estimates:

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the year. Actual results could differ from those estimates.

2. Investments:

(a) Cash and cash equivalents:

Included within cash and cash equivalents is two (2024 - two) cashable guaranteed investment certificates, bearing interest at 2.95% and 3% (2024 - 4.75% and 5.20%) and maturing on May 25, 2026 and January 17, 2026, respectively (2024 - April 15, 2025 and January 17, 2025).

(b) Long-term:

	2025	2024
Pooled funds:		
Fixed income	\$ 2,350,959	\$ 1,945,948
Canadian equity	2,918,599	2,518,375
Global equity	2,505,031	2,272,659
Alternative	1,105,090	1,141,654
	<u>\$ 8,879,679</u>	<u>\$ 7,878,636</u>

THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA/ SOCIÉTÉ DE LEUCÉMIE & LYMPHOME DU CANADA

Notes to Financial Statements (continued)

Year ended June 30, 2025

3. Capital and intangible assets:

			2025	2024
	Cost	Accumulated amortization	Net book value	Net book value
Office furniture and equipment	\$ 273,352	\$ 254,124	\$ 19,228	\$ 11,389
Website	234,060	234,060	–	25,964
Intangible asset - software	685,952	–	685,952	525,676
	\$ 1,193,364	\$ 488,184	\$ 705,180	\$ 563,029

The intangible asset - software is in the testing phase, and amortization will commence once it is put into service.

4. Accounts payable and accrued liabilities:

On July 1, 2004, the Organization entered into a business affiliation with The Leukemia & Lymphoma Society, a U.S. charity (the "Society"). The purpose of the affiliation is to create a single North American presence in support of research into the causes of, and cures for, leukemia, lymphoma, Hodgkin's disease and myeloma.

As part of the affiliation agreement, the Society has undertaken to pay certain trade payable amounts of the Organization for which the Society will be reimbursed. At June 30, 2025, the amount owed to the Society totalled \$336,441 (2024 - nil) and is included in accounts payable and accrued liabilities. The amount owing is non-interest bearing, is unsecured and has no specific repayment terms.

These transactions are in the normal course of operations and are recorded at the exchange amount, which is the amount of consideration established and agreed to by the related parties.

THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA/ SOCIÉTÉ DE LEUCÉMIE & LYMPHOME DU CANADA

Notes to Financial Statements (continued)

Year ended June 30, 2025

5. Deferred revenue:

	2025	2024
Balance, beginning of year	\$ 686,063	\$ 479,080
Amounts amortized into revenue	(1,349,318)	(664,185)
Amounts received	1,351,862	871,168
Balance, end of year	\$ 688,607	\$ 686,063

6. Externally restricted fund:

The Restricted fund includes unspent externally restricted donations and grants. Research expenses are recognized under the Externally restricted fund. Funds are transferred from the Operating fund by interfund transfer to cover these expenses.

During 2025, the Organization received donations of \$521,335 (2024 - \$244,000) externally restricted for research and patient support.

7. Internally restricted fund:

During 2024, the Board resolved to establish an operating reserve of \$6 million based on the following fiscal year's budget to ensure the Organization can continue its activities in the event of unforeseen circumstances.

8. Endowment fund:

The Endowment fund includes the following:

	2025	2024
Rae Endowment Fund	\$ 260,114	\$ 260,114
The United Food & Commercial Workers ("UFCW") Endowment Fund	90,000	90,000
Unspent investment income	114,590	276,681
	\$ 464,704	\$ 626,795

THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA/ SOCIÉTÉ DE LEUCÉMIE & LYMPHOME DU CANADA

Notes to Financial Statements (continued)

Year ended June 30, 2025

8. Endowment fund (continued):

Amounts restricted for endowment purposes are subject to externally imposed restrictions, stipulating that the principal be maintained permanently. The investment income earned on the Rae Endowment Fund is externally restricted to support research activities or to assist charitable organizations whose activities are within or similar to the Organization's objectives. The investment income earned on the UFCW Endowment Fund is externally restricted to fund scholarships for Canadian universities to distribute to students enrolled in courses related to leukemia research.

Investment income may be spent for purposes as specified in the restrictive endowment agreements. During the year, \$241,819 is used from the Rae Endowment Fund to support research on AML and Lymphoma (2024 - \$105,000 from UFCW Endowment Fund).

9. Investment and other income:

	2025	2024
Income from pooled funds	\$ 370,601	\$ 801,232
Interest	94,497	289,994
Net realized gain on sale of investments	10,405	375
Change in unrealized gain on investments	688,552	178,966
	<u>\$ 1,164,055</u>	<u>\$ 1,270,567</u>

Included in management and general expenses are investment management fees in the amount of \$53,452 (2024 - \$52,398).

10. Commitments:

(a) The Organization has committed to payments in future years for various rentals of space and delivery of services. Minimum annual payments under these agreements, including applicable taxes, are:

2026	\$ 1,325,000
2027	385,000
2028	105,000

THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA/ SOCIÉTÉ DE LEUCÉMIE & LYMPHOME DU CANADA

Notes to Financial Statements (continued)

Year ended June 30, 2025

10. Commitments (continued):

- (b) The Organization awards multi-year research grants to promote foundational studies. The continued funding of these grants is contingent upon the satisfactory completion of certain milestones stipulated in the agreements. The estimated future research grants are to be paid as follows:

2026	\$ 1,824,631
2027	1,454,316

11. Fundraising expenses:

Fundraising expenses consist of the following:

	2025	2024
Direct event fundraising (a)	\$ 927,730	\$ 994,449
General fundraising (b)	3,542,408	3,438,974
	\$ 4,470,138	\$ 4,433,423

- (a) Direct event fundraising expenses are costs directly related to putting on major events which include both fundraising and public education/patient support components. Fundraising expenses include, but are not limited to, participant incentives (such as T-shirts), venue rental fees (such as for city parks), etc.

- (b) General fundraising expenses are costs related to overall fundraising activities. These expenses include but are not limited to staffing, promotion, occupancy, printing and postage.

THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA/ SOCIÉTÉ DE LEUCÉMIE & LYMPHOME DU CANADA

Notes to Financial Statements (continued)

Year ended June 30, 2025

12. Expenses:

The following table summarizes direct expenses and allocated expenses, which are included in the statement of revenue and expenses:

			2025	2024
	Direct expenses	Allocated expenses	Total	Total
Research	\$ 3,095,641	\$ 457,085	\$ 3,552,726	\$ 3,203,555
Public education	17,972	2,738,943	2,756,915	2,497,463
Patient support	626,517	2,289,586	2,916,103	2,848,213
General fundraising	323,270	3,219,138	3,542,408	3,438,974
Management and general	1,010,684	1,960,234	2,970,918	3,149,078
	\$ 5,074,084	\$ 10,664,986	\$ 15,739,070	\$ 15,137,283

13. Guarantees:

In the normal course of business, the Organization enters into agreements that meet the definition of a guarantee. The Organization's primary guarantees are as follows:

- (a) The Organization has provided indemnities under lease agreements for the use of various operating facilities. Under the terms of these agreements, the Organization agrees to indemnify the counterparties for various items including, but not limited to, all liabilities, losses, suits and damages arising during, on or after the term of the agreement. The maximum amount of any potential future payment cannot be reasonably estimated.
- (b) The Organization indemnifies all directors and volunteers for various items including, but not limited to, all costs to settle suits or actions due to services provided to the Organization, subject to certain restrictions. The Organization has purchased liability insurance to mitigate the cost of any potential future suits or actions. The amount of any potential future payment cannot be reasonably estimated.

THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA/ SOCIÉTÉ DE LEUCÉMIE & LYMPHOME DU CANADA

Notes to Financial Statements (continued)

Year ended June 30, 2025

13. Guarantees (continued):

The nature of these indemnification agreements prevents the Organization from making a reasonable estimate of the maximum exposure due to the difficulties in assessing the amount of liability which stems from the unpredictability of future events and the unlimited coverage offered to counterparties. Historically, the Organization has not made any significant payments under such or similar indemnification agreements and, therefore, no amount has been accrued with respect to these agreements.

14. Financial risks:

The following risks have remained consistent with the prior year:

(a) Interest rate and currency risks:

The Organization is exposed to interest rate and currency risks with respect to its investments in fixed income investments and foreign currency-denominated investments because the fair value will fluctuate due to changes in market rates. The Organization does not currently enter into forward contracts to mitigate these risks.

(b) Liquidity risk:

Liquidity risk is the risk that the Organization will be unable to fulfill its obligations on a timely basis or at a reasonable cost. The Organization manages its liquidity risk by monitoring its operating requirements. The Organization prepares budget and cash forecasts to ensure it has sufficient funds to fulfill its obligations.

(c) Market risk:

Market risk arises as a result of trading equities and fixed income securities. Fluctuations in the market expose the Organization to risk of loss. The Investment Committee of the Organization monitors investment decisions and results.